原始来源记录
重大申请已提交
Inhibrx 计划于 2026 年第二季度初提交 ozekibart 的 BLA
该公司表示，将于 2026 年第二季度初提交 ozekibart 用于不可切除或转移性常规软骨肉瘤的 BLA。它还预计将于 2026 年第二季度公布结直肠癌扩展队列的 PFS 数据，并于 2026 年下半年与 FDA 召开会议，讨论在尤因肉瘤和四线结直肠癌中加速批准事宜。
关键事实
- 申报时间
- 2026年3月19日 20:01
- 事件
- 申请已提交
- 方向
- 中性
- 来源
- SEC 8-K
- 可信度
- 有来源
来源摘录
EX-99.1 2 exhibit99112312025.htm EX-99.1 Document Exhibit 99.1 Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results San Diego, CA, March 19, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the fourth quarter and fiscal year 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the “Former Parent”) to Sanofi S.A. (the “Acquirer”) and the Former Parent’s concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials. Upcoming Milestones • ozekibart (INBRX-109) ◦ We expect to submit the Biologics License Application (“BLA”) for ozekibart for the treatment of unresectable or metastatic conventi